Drug Search Results
More Filters [+]

Valopicitabine

Alternative Names: valopicitabine
Latest Update: 2010-06-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: HCV-NS5B Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Valopicitabine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis A|Hepatitis C, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NV-08A-006

P2

Completed

Hepatitis A|Hepatitis C, Chronic

None

Recent News Events

Date

Type

Title